Healthcare Professionals Report an Adverse Event Contact Global (EN)
Home / Pipeline

Development pipeline

Four medicines and three surgical platforms, built in eighteen months on $90 million of research and development. Updated 31 July 2026.

3Medicines in Phase 1
1Medicine in IND-enabling studies
1Device FDA cleared
2Devices in development

Medicines

CandidateIndicationTherapeutic areaModalityStage
BX-101Advanced solid tumours (KRAS G12D)OncologyTargeted protein degrader, oralPhase 1
BX-204Fibrostenotic Crohn's diseaseImmunology & InflammationTL1A antagonist, oralPhase 1
BX-412Elevated lipoprotein(a)CardiometabolicsiRNA, subcutaneousPhase 1
BX-308Amyotrophic lateral sclerosisNeuroscienceAntisense oligonucleotide, intrathecalIND-enabling

Surgical technology

PlatformWhat it doesIntended useStatus
Lumavue™Real-time tissue perfusion imagingGeneral, colorectal and reconstructive surgeryFDA 510(k) cleared
SealWeave™Bioresorbable staple-line sealantGastrointestinal and thoracic surgeryDesign verification
Axion OR™Robotic soft-tissue instrument platformMinimally invasive abdominal surgeryPrototype / preclinical
Important: BX-101, BX-204, BX-308 and BX-412 are investigational and have not been approved by any regulatory authority. Their safety and efficacy have not been established. SealWeave and Axion OR are investigational devices, limited by law to investigational use. This page is informational and is not an offer to sell or a solicitation to buy securities.

How the portfolio got here

2026

Into the clinic

BX-101, BX-204 and BX-412 all entered Phase 1 within a nine-month window. Lumavue received FDA 510(k) clearance in July.

2026

Stopped

Two discovery programs — a second-generation degrader series and an energy-based sealing device — were discontinued after failing the candidate-selection gate. The rationale for both is in our annual research summary.

2025

Founded and built

Company incorporated in March, Jupiter laboratories opened in August, Palm Beach Gardens engineering facility opened in November.